Outcomes of a large cohort of individuals with clinically ascertained
high-count monoclonal B-cell lymphocytosis

Sameer A. Parikh, Kari G. Chaffee, Melissa C. Larson, Paul J. Hampel, Timothy G. Call, Wei Ding, Saad S. Kenderian, Jose F. Leis, Asher A. Chanan-Khan, Michael J. Conte, Deborah Bowen, Susan M. Schwager, Susan L. Slager, Curtis A. Hanson, Neil E. Kay, and Tait D. Shanafelt

Disclosures: SAP has participated in advisory boards and received research support from Pharmacyclics and AstraZeneca; he was not personally compensated for the advisory board or the research support. TDS has received research funding from Pharmacyclics, Janssen, Genentech, Glaxosmithkline, Celgene, Cephalon, and Hospira; he was not personally compensated for the research support. NEK has received research funding from Pharmacyclics, Tolero and he is on DSMC for Gilead, Morpho-Sys, Infinity Pharm, Celgene and Cytomx Therapeutics; he was not personally compensated for the research support or the DSMC work. All other authors have no conflicts of interest to declare.

Contributions: SAP, NEK and TDS designed the research, collected, analyzed, and interpreted data, and wrote the manuscript; PH, TGC, WD, MJC, DAB, JFL, and AC-K cared for the patients, analyzed data, and critically reviewed the manuscript; SMS collected data for statistical analysis; KGC, MCL, and SLS, analyzed data, conducted statistical analyses, and critically reviewed the manuscript; CAH performed pathology review and critically reviewed the manuscript. All authors approved the manuscript in its final format.